Guidelines for lipid-based amphotericin B in SCT

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 306, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats

By Ibrahim Fady   Gershkovich Pavel   Sivak Olena   Wasan Ellen K.   Wasan Kishor M.  

Drug Development and Industrial Pharmacy, Vol. 39, Iss. 9, 2013-09 ,pp. : 1277-1283

Informa Healthcare

Access to resources Recommend Favorite

Assessing the Antifungal Activity of a New Oral Lipid-Based Amphotericin B Formulation Following Administration to Rats Infected with Aspergillus Fumigatus

By Risovic Verica   Rosland Mike   Sivak Olena   Wasan Kishor M.   Bartlett Karen  

Drug Development and Industrial Pharmacy, Vol. 33, Iss. 7, 2007-07 ,pp. : 703-707

Informa Healthcare

Access to resources Recommend Favorite

Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS ( R)), with commercial lipid-based formulations

By Fukui H.   Koike T.   Nakagawa T.   Saheki A.   Sonoke S.   Tomii Y.   Seki J.  

International Journal of Pharmaceutics, Vol. 267, Iss. 1, 2003-11 ,pp. : 101-112

Elsevier

Access to resources Recommend Favorite

Differences in human phospholipid transfer protein activity following incubation of Fungizone® compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma

By Henderson Ryan J.   Leon Carlos G.   Wasan Kishor M.  

Drug Development and Industrial Pharmacy, Vol. 35, Iss. 9, 2009-09 ,pp. : 1139-1146

Informa Healthcare

Access to resources Recommend Favorite